Redefining Recurrence Risk in HR+/HER2− Early Breast Cancer: Applying Evolving CDK4/6 Inhibitor Evidence to Adjuvant Treatment Decisions

CDK4/6 in EBC After ESMO: From Early Signals to Greater Clarity

MinuteCE®
ReachMD Healthcare Image
Media formats available:
Details
Episodes
Presenters
  • Overview

    Despite significant advances in adjuvant therapy for HR+/HER2− early breast cancer (EBC), disease recurrence remains a substantial clinical challenge worldwide. Recurrence risk may persist for decades and is increasingly understood as a continuum rather than a simple “high-risk” or “low-risk” classification. CDK4/6 inhibitors have transformed the treatment of HR+/HER2− advanced breast cancer when combined with endocrine therapy (ET). More recently, their role has expanded into early-stage, high-risk disease, with emerging data supporting their use as a standard of care option in the adjuvant setting. In this activity, expert faculty evaluate recently presented data that continue to define the role of CDK4/6 inhibitors in EBC and explore best practices for integrating these findings into clinical practice.

    *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative requires all faculty and planners to disclose financial relationships with ineligible companies. All relevant financial relationships have been reviewed and mitigated to ensure that the content is free from commercial bias.

    The following faculty and planners have disclosed relevant financial relationships with ineligible companies in the past 24 months.

    Faculty: 
    Javier Cortés, MD, PhD
    Head, International Breast Cancer Center
    Director, IOB Institute of Oncology
    Madrid, Spain

    Consulting Fees: AbbVie, AstraZeneca, Bioasis, Biocon, BioInvent, BioNTech, Bliss Biopharmaceutical, Boehringer Ingelheim, BridgeBio, Circle Pharma, Clovis Oncology, Daiichi Sankyo, Delcath Systems, Inc., Eisai, Ellipses, Expres2ion Biotechnologies, GEMoaB, Gilead, Hexagon Bio, HiberCell, Jazz Pharmaceuticals, Leuko, Lilly, Menarini, Merck Sharp & Dohme, Novartis, Pfizer, Relay Therapeutics, Reveal Genomics, Roche, Scorpion Therapeutics, Seattle Genetics, Stemline Therapeutics, Zuellig Pharma, Zymeworks
    Research: Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant Health, IQVIA, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Queen Mary University of London, Roche
    Ownership and Intellectual Property: Leuko (relative), MAJ3 Capital
    Patents:

    • Pharmaceutical combinations of a Pi3k Inhibitor and a microtubule destabilizing agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. ISSUED
    • Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cortés. US 2019/ 0338368 A1. LICENSED

    Stephanie L. Graff, MD
    Director, Breast Oncology
    University Health Cancer Institute
    Providence, RI, USA

    Consultant/Speaker/Advisory Board: AstraZeneca, Daiichi Sankyo/AstraZeneca, Genentech, Lilly, Menarini, Novartis, Pfizer, Wolters Kluwe
    Research: AstraZeneca/Daiichi Sankyo, Daiichi Sankyo, Jazz Pharmaceuticals, Lilly, Novartis
    Stock Ownership: HCA Healthcare

    Reviewers/Planners/Authors: 

    • Cindy Davidson has no relevant relationships to disclose.
    • Wilma M. Guerra has no relevant relationships to disclose.
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose. 
  • Learning Objectives

    Upon completion of this activity, learners should be better able to:

    • Differentiate available adjuvant CDK4/6 inhibitors based on pivotal trial evidence and key therapeutic characteristics
    • Select an appropriate adjuvant CDK4/6 inhibitor by integrating patient-, disease-, and treatment-specific characteristics
    • Develop monitoring and management strategies for adjuvant CDK4/6 inhibitor–related adverse events to support adherence and persistence
  • Target Audience

    This activity has been designed to meet the educational needs of oncologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals involved in managing patients with breast cancer. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.50 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.


    Global Learning Collaborative (GLC) designates this activity for a maximum of 0.50 contact hour(s)/0.05 CEUs of pharmacy continuing education credit. 
     
    The Universal Activity Number (UAN) for this program is JA0006235-0000-26-152-H01-P. This learning activity is knowledge-based. Upon successful completion of the activity, continuing education credit will be electronically submitted to the National Association of Boards of Pharmacy (NABP). Pharmacists with questions may contact NABP Customer Service at custserv@nabp.net.


    This activity has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®). 

    EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively. 
     
    Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™. 
     
    Through an agreement between the Royal College of Physicians and Surgeons of Canada and the European Board for Accreditation of Continuing Education for Health Professionals, Royal College MOC Section 1 credits are deemed to be substantively equivalent to EBAC CPD credits. 
     
    EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

  • Provider(s)/Educational Partner(s)

    Global Learning Collaborative (GLC) designs and executes continuing education rooted in evidence-based medicine, clinical need, knowledge gap analysis, and careful consideration of learner feedback. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology is founded on a commitment to continuing medical education and the innovative assessment of its effects on clinical practice. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Novartis Pharma AG.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.

    Reproduction Prohibited 
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date: Ongoing Program - Expiration date will be posted when all episodes are published.

NEW FEATURES:

Register

We're glad to see you're enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free